Department of Neurology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, People's Republic of China.
Institute of Translational Medicine, Shanghai University, Shanghai 200444, People's Republic of China.
Int J Nanomedicine. 2020 Sep 11;15:6779-6789. doi: 10.2147/IJN.S258311. eCollection 2020.
Alzheimer's disease (AD) is a neurodegenerative disorder that manifests as abnormal behavior and a progressive decline in memory. Although the pathogenesis of AD is due to the excessive deposition of amyloid β protein (Aβ) outside the neurons in the brain, evidence suggests that tau proteins may be a better target for AD therapy. In neurodegenerative diseases, a decrease in autophagy results in the failure to eliminate abnormally deposited or misfolded proteins. Therefore, induction of autophagy may be an effective way to eliminate tau proteins in the treatment of AD. We investigated the effects of polyethylene glycol (PEG)-ceramide nanomicelles on autophagy and on tau proteins in N2a, a murine neuroblastoma metrocyte cell line.
Ceramide is a sphingolipid bioactive molecule that induces autophagy. PEG-ceramide is a polymer that is composed of the hydrophobic chain of ceramide and the hydrophilic chain of PEG-2000. In this study, we prepared PEG-ceramide nanomicelles that were 10-20 nm in size and had nearly neutral zeta potential.
The results show that PEG-ceramide nanomicelles caused an increase in the LC3-II/LC3-I ratio, while p62 protein levels decreased. Confocal microscopy revealed a significant increase in the number of dots corresponding to autophagosomes and autolysosomes, which indicated autophagic activation. Moreover, PEG-ceramide nanomicelles induced tau degradation in N2a cells through autophagy.
In summary, we have confirmed that PEG-ceramide nanomicelles enhanced autophagic flux and degraded overexpressed human tau proteins in N2a cells by regulating the autophagy pathway. Thus, PEG-ceramide nanomicelles show great promise as agents to induce autophagy and degrade tau proteins in the treatment of AD.
阿尔茨海默病(AD)是一种神经退行性疾病,表现为异常行为和记忆逐渐衰退。尽管 AD 的发病机制是由于神经元外大量沉积的淀粉样β蛋白(Aβ),但有证据表明,tau 蛋白可能是 AD 治疗的更好靶点。在神经退行性疾病中,自噬的减少导致无法清除异常沉积或错误折叠的蛋白质。因此,诱导自噬可能是消除 AD 中 tau 蛋白的有效方法。我们研究了聚乙二醇(PEG)-神经酰胺纳米胶束对 N2a(一种鼠神经母细胞瘤母细胞系)中自噬和 tau 蛋白的影响。
神经酰胺是一种具有生物活性的鞘脂类物质,可诱导自噬。PEG-神经酰胺是一种聚合物,由神经酰胺的疏水链和亲水链 PEG-2000 组成。在本研究中,我们制备了大小为 10-20nm 且具有近中性 zeta 电位的 PEG-神经酰胺纳米胶束。
结果表明,PEG-神经酰胺纳米胶束导致 LC3-II/LC3-I 比值增加,而 p62 蛋白水平下降。共聚焦显微镜显示,自噬体和自溶体对应的斑点数量显著增加,表明自噬激活。此外,PEG-神经酰胺纳米胶束通过自噬诱导 N2a 细胞中的 tau 降解。
综上所述,我们已经证实,PEG-神经酰胺纳米胶束通过调节自噬途径增强了 N2a 细胞中的自噬流,并降解了过表达的人 tau 蛋白。因此,PEG-神经酰胺纳米胶束有望成为诱导自噬和降解 AD 中 tau 蛋白的药物。